VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE)

Q: What does CUSIP 92941V308 represent in this 13F holders report?

CUSIP 92941V308 is the security identifier for VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share in Q4 2023?

32 institutional investors reported VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share for Q4 2023. Use the holders table for investor-level position and value details.

CUSIP: 92941V308

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 18,514,484
Total 13F shares: 7,863,834
Share change: +7,385,635
Total reported value: $18,322,345
Price per share: $2.33
Number of holders: 32
Value change: +$17,207,859
Number of buys: 20
Number of sells: 5

Quarterly Holders Quick Answers

What is CUSIP 92941V308?
CUSIP 92941V308 identifies VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2024
Previous quarter: Q3 2023

Recent filing periods for CUSIP 92941V308:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PERCEPTIVE ADVISORS LLC	3/4/5	10%+ Owner	— class O/S missing	4,935,057	$11,251,930	—	16 Aug 2021	3/4/5
AI Biotechnology LLC	3/4/5	10%+ Owner	— class O/S missing	1,116,585	$2,545,814	—	01 Nov 2023	3/4/5
DSC Advisors, L.P.	13F	Company	0.62%	115,000	$460,000	—	30 Sep 2023	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.41%	75,771	$303,084	—	30 Sep 2023	13F
Andrew Saik	3/4/5	Chief Financial Officer	— class O/S missing	116,468	$265,547	—	28 May 2021	3/4/5
Matthew T. Wiley	3/4/5	Chief Commercial Officer	— class O/S missing	109,246	$249,081	—	30 Jun 2021	3/4/5
BlackRock Finance, Inc.	13F	Company	0.24%	44,939	$181,554	—	30 Sep 2023	13F
VANGUARD GROUP INC	13F	Company	0.24%	44,895	$181,376	—	30 Sep 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.15%	27,534	$110,167	—	30 Sep 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.14%	25,976	$105,000	—	30 Sep 2023	13F
STALEY CAPITAL ADVISERS INC	13F	Company	— class O/S missing	23,472	$94,827	—	30 Sep 2023	13F
STATE STREET CORP	13F	Company	0.06%	11,665	$46,660	—	30 Sep 2023	13F
US BANCORP \DE\	13F	Company	0.02%	4,444	$17,954	—	30 Sep 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.02%	3,423	$13,829	—	30 Sep 2023	13F
ROYAL BANK OF CANADA	13F	Company	0.01%	2,180	$9,000	—	30 Sep 2023	13F
MORGAN STANLEY	13F	Company	0.01%	2,179	$8,803	—	30 Sep 2023	13F
MB, LEVIS & ASSOCIATES, LLC	13F	Company	0.01%	1,041	$4,206	—	30 Sep 2023	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	269	$1,087	—	30 Sep 2023	13F
Russell Investments Group, Ltd.	13F	Company	0%	187	$748	—	30 Sep 2023	13F
UBS Group AG	13F	Company	0%	184	$744	—	30 Sep 2023	13F
JPMORGAN CHASE & CO	13F	Company	0%	146	$584	—	30 Sep 2023	13F
FEDERATED HERMES, INC.	13F	Company	0%	127	$513	—	30 Sep 2023	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	105	$424	—	30 Sep 2023	13F
Steward Partners Investment Advisory, LLC	13F	Company	0%	22	$89	—	30 Sep 2023	13F
Indiana Trust & Investment Management Co	13F	Company	0%	12	$48	—	30 Sep 2023	13F
Rex Bright	3/4/5	Director	— class O/S missing	20,500	—	—	19 Jul 2021	3/4/5

Institutional Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) as of Q4 2023

As of 31 Dec 2023, VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) was held by 32 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 7,863,834 shares. The largest 10 holders included Cormorant Asset Management, LP, EVENTIDE ASSET MANAGEMENT, LLC, CITADEL ADVISORS LLC, Soleus Capital Management, L.P., Parkman Healthcare Partners LLC, DSC Advisors, L.P., AlphaCentric Advisors LLC, Palo Alto Investors LP, PRELUDE CAPITAL MANAGEMENT, LLC, and Exome Asset Management LLC. This page lists 32 institutional shareholders reporting positions in this security for the Q4 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders

Q4 2023 holders

Holder diff

Investor	Q3 2023 Shares	Q4 2023 Shares	Share Diff	Share Chg %	Q3 2023 Value $	Q4 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.